KemPharm Analyst Ratings
KemPharm Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/17/2022 | 355.58% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 09/15/2022 | 355.58% | Canaccord Genuity | → $20 | Initiates Coverage On | → Buy |
| 08/17/2022 | 127.79% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 150.57% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 127.79% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 173.35% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 537.81% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -65.83% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -43.05% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -76.08% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -31.66% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 287.24% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 150.57% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/17/2022 | 355.58% | 康托·菲茨杰拉德 | → $20 | 开始承保 | →超重 |
| 09/15/2022 | 355.58% | 卡纳科特·格纳奇 | → $20 | 开始承保 | →购买 |
| 08/17/2022 | 127.79% | HC Wainwright公司 | $11 → $10 | 维护 | 买 |
| 01/31/2022 | 150.57% | HC Wainwright公司 | $10 → $11 | 升级 | 中性→购买 |
| 04/09/2021 | 127.79% | HC Wainwright公司 | $12 → $10 | 维护 | 中性 |
| 03/04/2021 | 173.35% | HC Wainwright公司 | $24 → $12 | 评级下调 | 购买→中性 |
| 01/25/2021 | 537.81% | 罗斯资本 | → $28 | 开始承保 | →购买 |
| 05/20/2020 | -65.83% | HC Wainwright公司 | $2.5 → $1.5 | 重申 | →购买 |
| 11/20/2019 | -43.05% | HC Wainwright公司 | $3 → $2.5 | 重申 | →购买 |
| 09/05/2019 | -76.08% | 罗斯资本 | $4.25 → $1.05 | 评级下调 | 购买→中性 |
| 06/19/2019 | -31.66% | HC Wainwright公司 | → $3 | 开始承保 | →购买 |
| 05/23/2018 | 287.24% | 詹尼·蒙哥马利·斯科特 | → $17 | 开始承保 | →购买 |
| 02/26/2018 | 150.57% | 卡纳科特·格纳奇 | $7 → $11 | 维护 | 买 |
What is the target price for KemPharm (KMPH)?
肯德基(KemPharm)的目标价是多少？
The latest price target for KemPharm (NASDAQ: KMPH) was reported by Cantor Fitzgerald on November 17, 2022. The analyst firm set a price target for $20.00 expecting KMPH to rise to within 12 months (a possible 355.58% upside). 4 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年11月17日报道了肯德基(纳斯达克：Kmph)的最新目标价。这家分析公司将目标价定为20美元，预计KMPH将在12个月内上涨至(可能上涨355.58%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for KemPharm (KMPH)?
肯德基(KemPharm)的最新分析师评级是多少？
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by Cantor Fitzgerald, and KemPharm initiated their overweight rating.
肯德基(纳斯达克代码：KMPH)的最新分析师评级是由坎托·菲茨杰拉德提供的，肯德姆启动了他们的增持评级。
When is the next analyst rating going to be posted or updated for KemPharm (KMPH)?
肯德基的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on November 17, 2022 so you should expect the next rating to be made available sometime around November 17, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与肯德基的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。KemPharm的上一次评级是在2022年11月17日提交的，所以你应该预计下一次评级将在2023年11月17日左右的某个时候公布。
Is the Analyst Rating KemPharm (KMPH) correct?
分析师对肯德基(KemPharm)的评级正确吗？
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a initiated with a price target of $0.00 to $20.00. The current price KemPharm (KMPH) is trading at is $4.39, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的KemPharm(KMPH)评级是以0.00美元至20.00美元的目标价启动的。肯德基目前的股价为4.39美元，在分析师的预测范围内。